CO5160246A1 - Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias - Google Patents
Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronariasInfo
- Publication number
- CO5160246A1 CO5160246A1 CO00006605A CO00006605A CO5160246A1 CO 5160246 A1 CO5160246 A1 CO 5160246A1 CO 00006605 A CO00006605 A CO 00006605A CO 00006605 A CO00006605 A CO 00006605A CO 5160246 A1 CO5160246 A1 CO 5160246A1
- Authority
- CO
- Colombia
- Prior art keywords
- prevention
- reduction
- coronary
- approximately
- coronary interventions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un método para la prevención o la reducción de episodios cardiovasculares asociados con intervenciones coronarias en mamíferos, particularmente en personas, que comprende administrar al sujeto ácido N-(3´,4´-dimetoxicinamoil)antranílico (N-5´) o una sal del mismo aceptable farmacéuticamente en una dosis diaria de aproximadamente 300 mg a aproximadamente 1.100 mg en asociación con la intervención coronaria.1El uso de ácido N-(3´,4´-dimetoxicinamoil)antranílico (N-5´), o una sal del mismo aceptable farmacéuticamente, en la confección de un medicamento para ser usado en la prevención o la reducción de episodios cardiovasculares asociados con intervenciones coronarias en un mamífero, en particular en una persona, cuando se administra en asociación con una intervención coronaria en una dosis diaria de aproximadamente 300 mg a aproximadamente 1.100 mg.2Una composición farmacéutica para ser usada en la prevención o la reducción de episodios cardiovasculares asociados con intervenciones coronarias en un mamífero, en particular en una persona, cuando se administra en asociación con una interverción coronaria en una dosis diaria de aproximadamente 300 mg a aproximadamente 1.100 mg, que comprende ácido N-(3´,4´-dimetoxicinamoil)antranílico (N-5´) o una sal del mismo aceptable farmacéuticamente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11846399P | 1999-02-03 | 1999-02-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5160246A1 true CO5160246A1 (es) | 2002-05-30 |
Family
ID=22378760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00006605A CO5160246A1 (es) | 1999-02-03 | 2000-02-03 | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1180027A4 (es) |
| JP (1) | JP2002536326A (es) |
| KR (1) | KR20010101933A (es) |
| CN (1) | CN1338930A (es) |
| AR (1) | AR022475A1 (es) |
| AU (1) | AU2978500A (es) |
| BR (1) | BR0007901A (es) |
| CA (1) | CA2361578A1 (es) |
| CO (1) | CO5160246A1 (es) |
| HU (1) | HUP0200148A3 (es) |
| IL (1) | IL144719A0 (es) |
| MX (1) | MXPA01007833A (es) |
| NO (1) | NO20013789L (es) |
| PL (1) | PL349926A1 (es) |
| TR (1) | TR200102262T2 (es) |
| WO (1) | WO2000045810A1 (es) |
| ZA (1) | ZA200106297B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8097650B2 (en) * | 2005-07-27 | 2012-01-17 | The Trustees Of Columbia University In The City Of New York | Method of treating a condition associated with phosphorylation of TASK-1 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2617407B2 (ja) * | 1992-09-14 | 1997-06-04 | キッセイ薬品工業株式会社 | 血管内膜細胞過剰増殖疾患の予防および治療剤 |
| KR19990044478A (ko) * | 1995-09-07 | 1999-06-25 | 간자와 무츠와 | 2-아실아미노벤즈아미드 유도체 및 혈관내막세포 과잉증식에 기인하는 질환의 예방 및 치료제 |
| US6019104A (en) * | 1996-12-30 | 2000-02-01 | Kissei Pharmaceutical Co., Ltd. | Method for the treatment or prevention of restenosis associated with coronary intervention |
-
2000
- 2000-02-02 PL PL00349926A patent/PL349926A1/xx not_active Application Discontinuation
- 2000-02-02 JP JP2000596930A patent/JP2002536326A/ja not_active Withdrawn
- 2000-02-02 CN CN00803386A patent/CN1338930A/zh active Pending
- 2000-02-02 MX MXPA01007833A patent/MXPA01007833A/es unknown
- 2000-02-02 IL IL14471900A patent/IL144719A0/xx unknown
- 2000-02-02 AU AU29785/00A patent/AU2978500A/en not_active Abandoned
- 2000-02-02 CA CA002361578A patent/CA2361578A1/en not_active Abandoned
- 2000-02-02 KR KR1020017009743A patent/KR20010101933A/ko not_active Application Discontinuation
- 2000-02-02 WO PCT/US2000/002611 patent/WO2000045810A1/en not_active Application Discontinuation
- 2000-02-02 HU HU0200148A patent/HUP0200148A3/hu unknown
- 2000-02-02 BR BR0007901-4A patent/BR0007901A/pt not_active Application Discontinuation
- 2000-02-02 TR TR2001/02262T patent/TR200102262T2/xx unknown
- 2000-02-02 AR ARP000100437A patent/AR022475A1/es unknown
- 2000-02-02 EP EP00908440A patent/EP1180027A4/en not_active Withdrawn
- 2000-02-03 CO CO00006605A patent/CO5160246A1/es unknown
-
2001
- 2001-07-31 ZA ZA200106297A patent/ZA200106297B/en unknown
- 2001-08-02 NO NO20013789A patent/NO20013789L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200148A3 (en) | 2003-06-30 |
| AR022475A1 (es) | 2002-09-04 |
| MXPA01007833A (es) | 2002-06-21 |
| IL144719A0 (en) | 2002-06-30 |
| AU2978500A (en) | 2000-08-25 |
| ZA200106297B (en) | 2002-07-31 |
| NO20013789D0 (no) | 2001-08-02 |
| PL349926A1 (en) | 2002-10-21 |
| NO20013789L (no) | 2001-09-28 |
| CN1338930A (zh) | 2002-03-06 |
| EP1180027A4 (en) | 2004-11-17 |
| KR20010101933A (ko) | 2001-11-15 |
| EP1180027A1 (en) | 2002-02-20 |
| TR200102262T2 (tr) | 2002-02-21 |
| JP2002536326A (ja) | 2002-10-29 |
| HUP0200148A2 (hu) | 2002-05-29 |
| CA2361578A1 (en) | 2000-08-10 |
| WO2000045810A1 (en) | 2000-08-10 |
| BR0007901A (pt) | 2001-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1138329B1 (en) | Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions | |
| CR6458A (es) | Composiciones de valdecoxib | |
| CY1105707T1 (el) | Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου | |
| DE69331409T2 (de) | Oral 1alpha-hydroxyprevitamin d | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| ES2188782T3 (es) | Formulaciones farmaceuticas que contienen darifenacina. | |
| AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| EA200000468A1 (ru) | Терапевтическая композиция для введения толтеродина с контролируемым высвобождением | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| BR9916860A (pt) | Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma | |
| AR008392A1 (es) | Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento | |
| ATE311928T1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| UY25798A1 (es) | Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico. | |
| CO5160246A1 (es) | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias | |
| AR025549A1 (es) | Mofetil micofelonato en asociacion con peg-ifn-alfa | |
| AR012638A1 (es) | Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional | |
| CO5150206A1 (es) | Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias | |
| AR062894A1 (es) | Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths) | |
| SE8804640L (sv) | Laekemedel omfattande cyklolinopeptide a | |
| KR950700063A (ko) | 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress) | |
| AU4918900A (en) | Interferon-beta use in the treatment of ewing's family of tumors | |
| ITRM20010695A1 (it) | Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del | |
| AR003957A1 (es) | Composicion farmaceutica para tratar un paciente mamifero que sufre una enfermedad vascular cronica progresiva (cpvd) | |
| FR2647014B1 (fr) | Composition medicamenteuse pour le traitement et la prevention des symptomes de l'insuffisance cardiaque, renfermant un agent alpha-stimulant vasoconstricteur comme principe actif |